Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin

被引:59
作者
David, Sascha [1 ]
Kuempers, Philipp [1 ]
Lukasz, Alexander [1 ]
Kielstein, Jan T. [1 ]
Haller, Hermann [1 ]
Fliser, Danilo [2 ]
机构
[1] Med Sch Hanover, Dept Med, Div Nephrol & Hypertens, D-30625 Hannover, Germany
[2] Univ Saarland, D-6650 Homburg, Germany
关键词
angiopoietin-2; angiotensin II receptor blocker; arterial hypertension; atherosclerosis; 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor; inter-cellular adhesion molecule-1; inflammation markers; olmesartan; statin; vascular cell adhesion molecule-1; C-REACTIVE PROTEIN; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-ARTERY-DISEASE; GROWTH-FACTOR LEVELS; II RECEPTOR BLOCKER; FACTOR-KAPPA-B; PHENOTYPIC HETEROGENEITY; CARDIOVASCULAR-DISEASE; ENDOTHELIAL-CELLS; RANDOMIZED TRIAL;
D O I
10.1097/HJH.0b013e32832be575
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Endothelial activation has emerged as an early event in the pathogenesis of cardiovascular disease. Angiopoietin-2 (Ang-2) has been identified as a nonredundant endothelial-specific facilitator of vascular responsiveness to inflammatory stimuli. We have earlier shown that angiotensin II receptor blocker (ARB) reduces mediators of vascular inflammation in hypertension and cardiovascular disease. We aimed at studying the effect of ARB and/or 3-hydroxy-3-methyl-glutaryl-CoA blockade on Ang-2 and the association between vascular inflammation markers and Ang-2 levels in hypertensive patients. Methods We assessed a panel of vascular inflammation markers and Ang-2 during 12 weeks of therapy with the ARB olmesartan (n = 94) or placebo (n = 96) in a prospective, double- blind, multicenter study in patients with essential hypertension (re-evaluation of the European Trial on Olmesartan and Pravastatin in Inflammation blood samples). Pravastatin was added to the double- blind therapy at week 6 in both arms. The association of demographic variables and inflammation markers with Ang- 2 has been investigated. Results Initial Ang- 2 concentrations in the study population were elevated compared with healthy controls (4.23 +/- 3.1 versus 0.88 +/- 0.43 ng/ml; P<0.0001). Ang-2 was higher in the elderly (P=0.01), women (P<0.001), and in the presence of atherosclerosis (P=0.02). Ang-2 correlated significantly with soluble TEK tyrosine kinase-2, interleukin-6, vascular cell adhesion molecule-1, and inter-cellular adhesion molecule-1. Surprisingly, neither monotherapy with olmesartan or pravastatin nor the combination therapy affected Ang- 2 concentrations. Conclusion Ang-2 concentrations are elevated in hypertensive patients, particularly those with atherosclerosis, possibly reflecting pronounced endothelial activation. ARBs effectively decreased several inflammatory mediators, but did not affect vascular responsiveness in an Ang-2-dependent manner. Elevated Ang-2 levels in hypertensive patients correlate with adhesion molecules. J Hypertens 27:1641-1647 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:1641 / 1647
页数:7
相关论文
共 36 条
  • [1] Phenotypic heterogeneity of the endothelium I. Structure, function, and mechanisms
    Aird, William C.
    [J]. CIRCULATION RESEARCH, 2007, 100 (02) : 158 - 173
  • [2] Phenotypic heterogeneity of the endothelium II. Representative vascular beds
    Aird, William C.
    [J]. CIRCULATION RESEARCH, 2007, 100 (02) : 174 - 190
  • [3] Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
    Albert, MA
    Danielson, E
    Rifai, N
    Ridker, PM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01): : 64 - 70
  • [4] Blood pressure, C-reactive protein, and risk of future cardiovascular events
    Blake, GJ
    Rifai, N
    Buring, JE
    Ridker, PM
    [J]. CIRCULATION, 2003, 108 (24) : 2993 - 2999
  • [5] Signaling and functions of angiopoietin-1 in vascular protection
    Brindle, NPJ
    Saharinen, P
    Alitalo, K
    [J]. CIRCULATION RESEARCH, 2006, 98 (08) : 1014 - 1023
  • [6] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [7] Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-κB, in mononuclear cells of normal subjects:: Evidence of an antiinflammatory action
    Dandona, P
    Kumar, V
    Aljada, A
    Ghanim, H
    Syed, T
    Hofmayer, D
    Mohanty, P
    Tripathy, D
    Garg, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) : 4496 - 4501
  • [8] DAVID S, 2004, AM J KIDNEY DIS
  • [9] Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation
    Fiedler, U
    Reiss, Y
    Scharpfenecker, M
    Grunow, V
    Koidl, S
    Thurston, G
    Gale, NW
    Witzenrath, M
    Rosseau, S
    Suttorp, N
    Sobke, A
    Herrmann, M
    Preissner, KT
    Vajkoczy, P
    Augustin, HG
    [J]. NATURE MEDICINE, 2006, 12 (02) : 235 - 239
  • [10] Angiopoietins: a link between angiogenesis and inflammation
    Fiedler, Ulrike
    Augustin, Helimut G.
    [J]. TRENDS IN IMMUNOLOGY, 2006, 27 (12) : 552 - 558